Use of non-GAAP measures:
In addition to gaAP monetary measures as explained in our Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 10, 2020, the Company, in this press release, included certain measures other than GAAP. The non-GAAP loss attributable to non-unusual shareholders is explained through the Company as a GAAP net loss attributable to non-unusual shareholders, less net losses from our public partners Avenue, Checkpoint and Mustang, as well as Caelum. In addition, the Company also provided a loss of Non-GAAP Fortress attributable to non-unusual shareholders which is a modified EBITDA calculation that begins with non-GAAP loss attributable to non-unusual shareholders and share-based reimbursement expense, non-cash interest expense. , licensing and debt relief and depreciation.
Reconciliation with non-GAAP and progression and general and administrative expenses:
Company Contacts: Jaclyn Jaffe and William BegienFortress Biotech, Inc. (781) [email protected]
Investor Relations Contact: Daniel Ferry LifeSci Advisors, LLC (617) [email protected]
Media contact: Tony Plohoros 6 Degrees (908) [email protected]
1 Includes upcoming candidate products in Fortress, controlled and majority-owned partners, and partners in which Fortress has significant minority stakes. As used here, the words “we”, “our” and “our” would possibly refer to Fortress or in conjunction with our affiliates and partners, depending on the context.